Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06797401

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06797401
  • EudraCT 2023-510369-92
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06797401. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Condition
Dyslipidemias
Intervention (Drug)
RBD5044
Intervention (Drug)
Placebo
Lead sponsor
Ribocure Pharmaceuticals AB (class: industry)

Record details

Record id
cardio:ct-nct06797401
Content hash
cb66e318f61062eed07306a9e8dbbe8cd6e3731fea62f842f6fe83455c54b1a1